Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase 7B (PDE7B) is a 446-amino acid enzyme with a molecular mass of ~50 kDa, most highly expressed in pancreas, brain, heart, thyroid, skeletal muscle, and other tissues. It hydrolyzes cAMP to 5'-AMP, regulating physiological processes dependent on cyclic nucleotide signaling. PDE7B belongs to the PDE7 gene family and has high affinity for cAMP, with little activity for cGMP. PDE7B is inhibited in vitro by several nonselective and semiselective phosphodiesterase inhibitors, supporting its characterization as a druggable target. Its biological and potential disease roles are subject to ongoing investigation, including speculation about implication in pancreatic function, neural activity, and inflammatory signaling.
Inhibition of PDE7B increases intracellular cAMP, affecting downstream cell signaling Drugs act as competitive inhibitors of the catalytic domain
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 7B (PDE7B).